Drugs / Ad26/protein preF RSV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05242432 | Apr 2022 → Mar 2023 | respiratory syncytial virus infectious disease | Janssen Pharmaceutical K.K. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26/protein preF RSV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05242432 ↗ |
| Modality | Vaccine | “Ad26.RSV.preF/RSV preF-based vaccine” PMID 40319702 ↗ May 2025 |
| Route | Intramuscular | “Ad26/protein preF RSV vaccine will be administered as an IM injection.” NCT05242432 ↗ |